Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas

doi:10.5306/wjco.v3.i3.32

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6386)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

558

HTML

5390

Figures (1-1)

229

Tables (1-1)

209

Sum=6386

Mar 10, 2012 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Mar 10, 2012; 3(3): 32-42
Published online Mar 10, 2012. doi: 10.5306/wjco.v3.i3.32

Table 1 Potential therapeutic targets in melanoma stem/progenitor cells and their progenies

Targeted deregulated element	Name of inhibitory agent
mAb against stem cell-like surface marker
CD133	Anti-CD133 mAb
ABCB5	Anti-ABCB5 mAb
Growth factor signaling inhibitor
EGFR (erbB1) antibody	mAb-C225, cetuximab (IMC-C225), IMC-1121B
EGFR-TKI	Gefitinib, erlotinib, AG1478, PD153035
Anti-EGF antibody	ABX-EGF
Pan-erbB1/erbB2/erbB3/erbB4-TKI	Cl1033
MET	SUI1274
Hedgehog	Anti-SHH antibody, SMO inhibitor (cyclopamine, GDC-0449, BMS-833923, NVP-LDE225, IPI-926 IPI-269609)
Wnt/β-catenin	Anti-Wnt antibody, WIF-1
Notch	γ-secretase inhibitor (DAPT, MK-0752,GSI-18)
Nodal/Cripto	LEFTY, Anti-Cripto mAb
KIT	Imatinib mesylate, dasatinib
HA/CD44	Anti-CD44 mAb, soluble CD44 protein
VEGF	Anti-VEGF antibody (bevacizumab)
VEGFR2	Anti-VEGFR-2 mAb (DC101)
VEGFR2/EGFR/RET	Vandetanib (ZD6474)
VEGFRs, PDGFRs, KIT	Sunitinib
B-Raf, C-Raf, KIT, PDGFRs, VEGFR2 and 3	Sorafenib
ECM component/integrin	Anti-integrin antibody
CXCR4	AMD3100
Intracellular signaling inhibitor
B-RafE600V	PLX 4032, PLX4720
MEK1/2	AZD6244 (ARRY-142886), PD0325901
PI3K	LY294002
mTOR	Rapamycin, CCl-779,
PI3K/mTOR	PI-103
NF-κB	IkBα inhibitor, sulfasalazine, bortezomib (PS-341) salinosporamides A (NPI-0052), parthenolide
COX-2	NS-396, etodolax, celecoxib, rofecoxib
Immunomodulatory agent
Immune and/or vascular systems	Imiquimod, INF-α, IL-2, IL-21, anti-CTLA-4, mAb (ipilimumab “MDX 010”and tremelimumab “CP-675, 206”)

CTLA-4: Cytotoxic T lymphocyte-associated antigen 4; DAPT: N-(N-3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; ECM: Extracellular matrix; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; IκBα: Inhibitor of nuclear factor-κBα; IL: Interleukin; INF: Interferon; mAb: Monoclonal antibody; NF-κB: Nuclear factor-kappaB; PDGFRs: Platelet-derived growth factor receptors; MET: Hepatocyte growth factor receptor; PI3K: Phosphatidylinositol 3’-kinase; SMO: Smoothened; TKI: Tyrosine kinase inhibitor; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; WIF-1: Wingless inhibitory factor-1; Wnt: Wingless ligand.

Citation: Mimeault M, Batra SK. Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol 2012; 3(3): 32-42
URL: https://www.wjgnet.com/2218-4333/full/v3/i3/32.htm
DOI: https://dx.doi.org/10.5306/wjco.v3.i3.32